SpringWorks Therapeutics, Inc. SWTX
Set alert
46.99 0.00 0.00%
At close · Jul 1
46.99 Day range 46.99
52-week range unavailable
- Open
- 46.99
- Prev close
- 46.99
- Mkt cap
- 3.54B
- Vol
- 5.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 46.99
- High
- 46.99
- Forward P/E
- -21.96
- Beta
- 0.70
- Short ratio
- 1.46
- Inst. own
- 87.40%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 46.50
- 200-d avg
- 41.63
- 1y target
- 47.00
Analyst view
Consensus: none
Price target (mean) 47.00
Ratings (0m) 6 0 buy · 6 hold · 0 sell
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.97 | -0.97 – -0.97 | -0.54 | -79.6% | 73.39M | +22.9% | 1 |
| Next quarter | -1.05 | -1.05 – -1.05 | -0.72 | -45.8% | 86.45M | +75.3% | 1 |
| Current year | -4.16 | -4.16 – -4.16 | -3.48 | -19.5% | 316.43M | +65.2% | 1 |
| Next year | -1.15 | -2.74 – 0.31 | -4.16 | +72.4% | 571.58M | +80.6% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 12, 2025 | Guggenheim | Reiterated | Neutral | Neutral |
| Apr 30, 2025 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Apr 29, 2025 | Guggenheim | Downgrade | Buy | Neutral |
| Apr 29, 2025 | TD Cowen | Downgrade | Buy | Hold |
| Apr 28, 2025 | Barclays | Downgrade | Overweight | Equal-Weight |
| Feb 24, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 21, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Feb 12, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Feb 12, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Feb 12, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 8, 2025 | Guggenheim | Maintained | Buy | Buy |
| Nov 20, 2024 | Evercore ISI Group | Initiated | — | Outperform |
| Nov 12, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 4, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Aug 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 4, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 6, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 6, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 6, 2024 | JP Morgan | Maintained | Overweight | Overweight |
| Feb 29, 2024 | Barclays | Maintained | Overweight | Overweight |
| Feb 26, 2024 | Wedbush | Maintained | Outperform | Outperform |
| Jan 25, 2024 | Barclays | Maintained | Overweight | Overweight |
| Nov 29, 2023 | Goldman Sachs | Maintained | Buy | Buy |
| Nov 29, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 28, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 20, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 9, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 24, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 7, 2023 | HC Wainwright & Co. | Maintained | Buy | Buy |